{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T09:37:42Z","timestamp":1790933862783,"version":"4.1.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Heart Failure"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.jchf.2022.12.012","type":"journal-article","created":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T14:10:56Z","timestamp":1681308656000},"page":"749-759","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Prevalent and Incident Anemia in PARADIGM-HF and the Effect of Sacubitril\/Valsartan"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1795-7445","authenticated-orcid":false,"given":"James P.","family":"Curtain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7019-7329","authenticated-orcid":false,"given":"Carly","family":"Adamson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kieran F.","family":"Docherty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pardeep S.","family":"Jhund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshay S.","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin P.","family":"Lefkowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adel R.","family":"Rizkala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean L.","family":"Rouleau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Swedberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Zile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D.","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milton","family":"Packer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6317-3975","authenticated-orcid":false,"given":"John J.V.","family":"McMurray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchf.2022.12.012_bib1","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.hfc.2010.03.002","article-title":"Pathophysiology of anemia in heart failure","volume":"6","author":"Anand","year":"2010","journal-title":"Heart Fail Clin"},{"key":"10.1016\/j.jchf.2022.12.012_bib2","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.632318","article-title":"The prognostic significance of anemia in patients with heart failure: a meta-analysis of studies from the last decade","volume":"8","author":"Xia","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.jchf.2022.12.012_bib3","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.hfc.2020.12.002","article-title":"Anemia and management of heart failure patients","volume":"17","author":"Beladan","year":"2021","journal-title":"Heart Fail Clin"},{"key":"10.1016\/j.jchf.2022.12.012_bib4","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1056\/NEJMoa1214865","article-title":"Treatment of anemia with darbepoetin alfa in systolic heart failure","volume":"368","author":"Swedberg","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2022.12.012_bib5","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/qjmed\/hcv049","article-title":"Renin-angiotensin system inhibitors linked to anemia: a systematic review and meta-analysis","volume":"108","author":"Cheungpasitporn","year":"2015","journal-title":"QJM"},{"key":"10.1016\/j.jchf.2022.12.012_bib6","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/j.1365-2125.1992.tb05644.x","article-title":"Effect of angiotensin converting enzyme inhibitors on erythropoietin concentrations in healthy volunteers","volume":"34","author":"Pratt","year":"1992","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jchf.2022.12.012_bib7","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1161\/CIRCULATIONAHA.104.512988","article-title":"Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure: results from Val-HeFT","volume":"112","author":"Anand","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2022.12.012_bib8","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.jacc.2004.10.038","article-title":"Angiotensin-converting enzyme inhibitor as a risk factor for the development of anemia, and the impact of incident anemia on mortality in patients with left ventricular dysfunction","volume":"45","author":"Ishani","year":"2005","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2022.12.012_bib9","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1182\/blood.V98.9.2697","article-title":"Negative feedback on the effects of stem cell factor on hematopoiesis is partly mediated through neutral endopeptidase activity on substance P: a combined functional and proteomic study","volume":"98","author":"Joshi","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.jchf.2022.12.012_bib10","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1163\/156855900300109530","article-title":"Effects of a membrane-metallopeptidase blocking agent thiorphan in long-term cultures of human bone marrow","volume":"30","author":"Stanovi\u0107 Janda","year":"2000","journal-title":"Haematologia (Budap)"},{"key":"10.1016\/j.jchf.2022.12.012_bib11","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2022.12.012_bib12","unstructured":"Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. World Health Organization. Accessed September 21, 2021. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/85839\/WHO_NMH_NHD_MNM_11.1_eng.pdf"},{"key":"10.1016\/j.jchf.2022.12.012_bib13","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2022.12.012_bib14","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jchf.2022.12.012_bib15","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1093\/eurheartj\/ehl012","article-title":"The impact of new onset anaemia on morbidity and mortality in chronic heart failure: results from COMET","volume":"27","author":"Komajda","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jchf.2022.12.012_bib16","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1161\/CIRCULATIONAHA.105.549121","article-title":"Levels of hematopoiesis inhibitor N-acetyl-seryl-aspartyl-lysyl-proline partially explain the occurrence of anemia in heart failure","volume":"112","author":"van der Meer","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2022.12.012_bib17","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1046\/j.1440-1681.2001.03560.x","article-title":"Angiotensin I-converting enzyme and metabolism of the haematological peptide N-acetyl-seryl-aspartyl-lysyl-proline","volume":"28","author":"Azizi","year":"2001","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.jchf.2022.12.012_bib18","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1161\/CIRCULATIONAHA.121.054892","article-title":"Effect of neprilysin inhibition on left ventricular remodeling in patients with asymptomatic left ventricular systolic dysfunction late after myocardial infarction","volume":"144","author":"Docherty","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2022.12.012_bib19","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1161\/CIRCULATIONAHA.118.030099","article-title":"Anemia and iron deficiency in heart failure: current concepts and emerging therapies","volume":"138","author":"Anand","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2022.12.012_bib20","first-page":"629","article-title":"Elevated plasma B-type natriuretic peptide concentrations directly inhibit circulating neprilysin activity in heart failure","volume":"3","author":"Vodovar","year":"2015","journal-title":"J\u00a0Am Coll Cardiol HF"},{"key":"10.1016\/j.jchf.2022.12.012_bib21","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1002\/ejhf.1342","article-title":"Effects of sacubitril\/valsartan on neprilysin targets and the metabolism of natriuretic peptides in chronic heart failure: a mechanistic clinical study","volume":"21","author":"Nougu\u00e9","year":"2000","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2022.12.012_bib22","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1186\/s12872-022-02647-0","article-title":"Effects of sacubitril\/valsartan on biomarkers of fibrosis and inflammation in patients with heart failure with reduced ejection fraction","volume":"22","author":"Bolla","year":"2022","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.jchf.2022.12.012_bib23","doi-asserted-by":"crossref","first-page":"473","DOI":"10.2478\/acph-2021-0030","article-title":"Effect of sacubitril\/valsartan on inflammation and oxidative stress in doxorubicin-induced heart failure model in rabbits","volume":"71","author":"Yu","year":"2021","journal-title":"Acta Pharmaceutica"},{"key":"10.1016\/j.jchf.2022.12.012_bib24","first-page":"174","article-title":"C-reactive protein reduction with sacubitril-valsartan treatment in heart failure patients","volume":"10","author":"Goncalves","year":"2020","journal-title":"Am J Cardiovasc Dis"},{"key":"10.1016\/j.jchf.2022.12.012_bib25","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1016\/S0140-6736(20)32339-4","article-title":"Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial","volume":"396","author":"Ponikowski","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jchf.2022.12.012_bib26","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/ejhf.2132","article-title":"Effect of dapagliflozin on anaemia in DAPA-HF","volume":"23","author":"Docherty","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2022.12.012_bib27","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S2213-8587(20)30300-4","article-title":"Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial","volume":"8","author":"Oshima","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jchf.2022.12.012_bib28","doi-asserted-by":"crossref","first-page":"4517","DOI":"10.1002\/ehf2.13615","article-title":"Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA-REG OUTCOME trial","volume":"8","author":"Fitchett","year":"2021","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.jchf.2022.12.012_bib29","doi-asserted-by":"crossref","first-page":"356","DOI":"10.2337\/dc17-1096","article-title":"How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME trial","volume":"41","author":"Inzucchi","year":"2018","journal-title":"Diabetes Care"}],"container-title":["JACC: Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177923000318?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177923000318?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:03:05Z","timestamp":1761973385000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213177923000318"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":29,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S2213177923000318"],"URL":"https:\/\/doi.org\/10.1016\/j.jchf.2022.12.012","relation":{},"ISSN":["2213-1779"],"issn-type":[{"value":"2213-1779","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevalent and Incident Anemia in PARADIGM-HF and the Effect of Sacubitril\/Valsartan","name":"articletitle","label":"Article Title"},{"value":"JACC: Heart Failure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchf.2022.12.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}